



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

PROTOCOL CODE: GIRAJCOX

(Page 1 of 1)

| | | |
|--|---------------------|--|
| DOCTOR'S ORDERS | | Ht _____ cm Wt _____ kg BSA _____ m ² |
| REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form | | |
| DATE: | To be given: | Cycle(s) #: |
| Date of Previous Cycle: _____ | | |
| <input type="checkbox"/> Delay treatment _____ week(s) <input type="checkbox"/> CBC & Diff day of treatment | | |
| May proceed with doses as written if within 96 hours ANC greater than or equal to $1.2 \times 10^9/L$, platelets greater than or equal to $75 \times 10^9/L$, creatinine clearance greater than 50 mL/minute | | |
| Dose modification for: <input type="checkbox"/> Hematology <input type="checkbox"/> Other Toxicity _____ | | |
| Proceed with treatment based on blood work from: _____ | | |
| PREMEDICATIONS: Patient to take own supply. RN/Pharmacist to confirm _____ ondansetron 8 mg PO prior to treatment dexamethasone <input type="checkbox"/> 8 mg or <input type="checkbox"/> 12 mg (select one) PO prior to treatment (omit if below dexamethasone IV premedication ordered) <input type="checkbox"/> For prior oxaliplatin hypersensitivity reactions (Grade 1 or 2): 45 minutes prior to oxaliplatin: dexamethasone 20 mg IV in 50 mL NS over 15 minutes 30 minutes prior to oxaliplatin: diphenhydramine 50 mg IV in NS 50 mL over 15 minutes and famotidine 20 mg IV in NS 100 mL over 15 minutes (Y-site compatible) NO ice chips <input type="checkbox"/> Other: _____ | | |
| ** Have Hypersensitivity Reaction Tray & Protocol Available** | | |
| TREATMENT: All lines to be primed with D5W <input type="checkbox"/> Repeat in three weeks oxaliplatin $130 \text{ mg/m}^2 \times \text{BSA} =$ _____ mg <input type="checkbox"/> Dose Modification: _____ mg/m ² x BSA = _____ mg IV in 250 to 500 mL D5W over 2 hours For moderate vascular pain during oxaliplatin peripheral administration 250 mL D5W at maximum rate of 125 mL/h concurrently with oxaliplatin prn OR <input type="checkbox"/> 500 mL D5W at maximum rate of 250 mL/h concurrently with oxaliplatin prn capecitabine 1000 mg/m^2 or _____ x BSA x (_____ %) = _____ mg PO BID x 14 days (refer to <u>Capecitabine Suggested Tablet Combination Table</u> for dose rounding) | | |
| RETURN APPOINTMENT ORDERS | | |
| <input type="checkbox"/> Return in three weeks for Doctor and Cycle _____ <input type="checkbox"/> Return in six weeks for Doctor and Cycle _____ & _____. Book treatment x 2 cycles. <input type="checkbox"/> Last Cycle. Return in _____ week(s) | | |
| CBC & Diff, creatinine, total bilirubin, ALT prior to each cycle If clinically indicated: <input type="checkbox"/> CEA <input type="checkbox"/> CA19-9 <input type="checkbox"/> ECG <input type="checkbox"/> alkaline phosphatase <input type="checkbox"/> albumin <input type="checkbox"/> GGT <input type="checkbox"/> sodium <input type="checkbox"/> potassium <input type="checkbox"/> INR weekly <input type="checkbox"/> INR prior to each cycle <input type="checkbox"/> Other tests: <input type="checkbox"/> Weekly nursing assessment for (specify concern): _____ <input type="checkbox"/> Consults: <input type="checkbox"/> See general orders sheet for additional requests. | | |
| DOCTOR'S SIGNATURE: | | SIGNATURE: UC: |